Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (311-320 of 353) with videos related to

Pageof 36
Sort By:
American Heart Journal|August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY LibraryJohn L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
European Heart Journal Open|August 4, 2022
Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammationPaul C Cremer, Calvin C Sheng, Debasis Sahoo, et al.
Journal of the American College of Cardiology|September 1, 2024
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT TrialBenjamin M Scirica, A Michael Lincoff, Ildiko Lingvay, et al.
Lancet (London, England)|August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialJohn Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Diabetes & Vascular Disease Research|October 21, 2017
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromesStefano Savonitto, Nuccia Morici, Anna Nozza, et al.
American Heart Journal|September 27, 2023
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristicsStephen J Nicholls, Deepak L Bhatt, John B Buse, et al.
International Journal of Cardiology|June 22, 2017
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trialsGianluca Campo, Rita Pavasini, Giampaolo Morciano, et al.
Diabetes Care|April 6, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDNaveed Sattar, Hertzel C Gerstein, David D'Alessio, et al.
JAMA|August 12, 2004
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialA Michael Lincoff, Neal S Kleiman, Dean J Kereiakes, et al.
The New England Journal of Medicine|November 17, 2009
Platelet inhibition with cangrelor in patients undergoing PCIRobert A Harrington, Gregg W Stone, Steven McNulty, et al.
Pageof 36

Showing results (311-320 of 353) with videos related to

Sort By:
Pageof 36
American Heart Journal|August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY LibraryJohn L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
European Heart Journal Open|August 4, 2022
Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammationPaul C Cremer, Calvin C Sheng, Debasis Sahoo, et al.
Journal of the American College of Cardiology|September 1, 2024
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT TrialBenjamin M Scirica, A Michael Lincoff, Ildiko Lingvay, et al.
Lancet (London, England)|August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialJohn Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Diabetes & Vascular Disease Research|October 21, 2017
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromesStefano Savonitto, Nuccia Morici, Anna Nozza, et al.
American Heart Journal|September 27, 2023
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristicsStephen J Nicholls, Deepak L Bhatt, John B Buse, et al.
International Journal of Cardiology|June 22, 2017
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trialsGianluca Campo, Rita Pavasini, Giampaolo Morciano, et al.
Diabetes Care|April 6, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDNaveed Sattar, Hertzel C Gerstein, David D'Alessio, et al.
JAMA|August 12, 2004
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialA Michael Lincoff, Neal S Kleiman, Dean J Kereiakes, et al.
The New England Journal of Medicine|November 17, 2009
Platelet inhibition with cangrelor in patients undergoing PCIRobert A Harrington, Gregg W Stone, Steven McNulty, et al.
Pageof 36